Clinical Trial Update: IL-1-receptor Antagonist During Cephalic Phase of Insulin Secretion in Health and Type 2 Diabetes [Phase 2]

View source ↗

Summary

A Phase 2 trial of an interleukin-1 receptor antagonist evaluating cephalic-phase insulin secretion in healthy individuals and people with Type 2 diabetes has b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• Anakinra (anakinra)

Snippet

Sponsor: University Hospital, Basel, Switzerland | Conditions: Diabetes Mellitus Type 2 in Obese, Inflammation | Phase 2 | Status: TERMINATED